Robert W. Baird Trims Henry Schein (NASDAQ:HSIC) Target Price to $82.00

Henry Schein (NASDAQ:HSIC) had its price objective decreased by Robert W. Baird from $92.00 to $82.00 in a report published on Wednesday morning, Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

A number of other research firms have also recently weighed in on HSIC. UBS Group cut their price target on Henry Schein from $82.00 to $80.00 and set a neutral rating for the company in a report on Wednesday, May 8th. Evercore ISI reduced their target price on shares of Henry Schein from $72.00 to $70.00 and set an in-line rating on the stock in a report on Wednesday. Piper Sandler reiterated an overweight rating and set a $86.00 price target on shares of Henry Schein in a report on Friday, June 21st. Barrington Research reduced their price objective on shares of Henry Schein from $92.00 to $82.00 and set an outperform rating on the stock in a research note on Wednesday. Finally, Baird R W upgraded shares of Henry Schein from a hold rating to a strong-buy rating in a research report on Monday, July 22nd. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of Hold and a consensus price target of $77.90.

Henry Schein Price Performance

NASDAQ HSIC traded up $0.78 during trading hours on Wednesday, reaching $68.94. The company’s stock had a trading volume of 2,399,686 shares, compared to its average volume of 1,227,769. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.02 and a current ratio of 1.75. The company’s 50-day moving average is $67.73 and its two-hundred day moving average is $71.55. Henry Schein has a fifty-two week low of $60.01 and a fifty-two week high of $82.63. The stock has a market cap of $8.83 billion, a PE ratio of 23.29, a PEG ratio of 1.80 and a beta of 0.87.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, August 6th. The company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.22 by $0.01. Henry Schein had a net margin of 3.12% and a return on equity of 13.51%. The business had revenue of $3.10 billion for the quarter, compared to analyst estimates of $3.27 billion. During the same period in the prior year, the business earned $1.31 earnings per share. The company’s quarterly revenue was up .0% on a year-over-year basis. Analysts forecast that Henry Schein will post 5.16 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. KBC Group NV increased its stake in Henry Schein by 163.5% during the fourth quarter. KBC Group NV now owns 521,964 shares of the company’s stock worth $39,518,000 after acquiring an additional 323,901 shares during the last quarter. Duality Advisers LP acquired a new stake in Henry Schein during the 4th quarter worth approximately $1,561,000. Everett Harris & Co. CA raised its holdings in Henry Schein by 13.9% in the first quarter. Everett Harris & Co. CA now owns 119,257 shares of the company’s stock valued at $9,006,000 after buying an additional 14,580 shares during the period. UniSuper Management Pty Ltd lifted its position in Henry Schein by 611.8% during the first quarter. UniSuper Management Pty Ltd now owns 13,695 shares of the company’s stock valued at $1,034,000 after buying an additional 11,771 shares in the last quarter. Finally, Sprucegrove Investment Management Ltd. lifted its position in Henry Schein by 14.2% during the fourth quarter. Sprucegrove Investment Management Ltd. now owns 220,491 shares of the company’s stock valued at $16,693,000 after buying an additional 27,500 shares in the last quarter. 96.62% of the stock is owned by hedge funds and other institutional investors.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.